Recurrent Coronary Artery Vasospasm in a Patient with Hepatocellular Carcinoma Treated with Sorafenib: a Case Report and Literature Reviewopen access
- Authors
- Lim, Dae Hyun; Yoon, Jai Hoon; Jun, Dae Won; Lee, Oh Young; Yoon, Byung Chul; Lee, Hang Rak; Kim, Kyung Soo; Choi, Ho Soon
- Issue Date
- Mar-2020
- Publisher
- The Korean Liver Cancer Association
- Keywords
- Sorafenib; Coronary artery vasospasm; Variant angina; Tyrosine kinase inhibitor; Vascular endothelial growth factor inhibitor
- Citation
- Journal of Liver Cancer, v.20, no.1, pp.67 - 71
- Indexed
- KCI
- Journal Title
- Journal of Liver Cancer
- Volume
- 20
- Number
- 1
- Start Page
- 67
- End Page
- 71
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/10692
- DOI
- 10.17998/jlc.20.1.67
- ISSN
- 2288-8128
- Abstract
- Tyrosine kinase inhibitors are widely used as targeted treatments for various malignancies. Sorafenib is an orally active tyrosine kinase inhibitor that blocks the signaling pathways of several growth factors. Its use is approved for various malignancies such as unresectable hepatocellular carcinoma, renal cell carcinoma, and gastrointestinal stromal tumors. Several adverse effects have been reported in the literature; however, cardiotoxicity is rare. We present a case of recurrent coronary vasospasm caused by short-term administration (5 days) of sorafenib. Since it caused refractory ischemia after re-administration, we had no choice but to stop the treatment.
- Files in This Item
-
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/10692)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.